Lanreotide Sun (Lanreotide)

• Lanreotide is a somatostatin analog used in endocrine disorders.
• Acromegaly: reduces excess growth hormone secretion and helps control disease activity.
• Neuroendocrine tumors: suppresses tumor‑related hormone release and may slow disease progression.
• Carcinoid syndrome associated with neuroendocrine tumors: helps control flushing and diarrhea symptoms.

• Lanreotide is a synthetic analogue of somatostatin that binds with high affinity to somatostatin receptor subtypes (SSTR2, SSTR5) on pituitary and neuroendocrine cells. Receptor activation inhibits adenylate cyclase, reduces intracellular calcium, and suppresses the secretion of growth hormone, insulin‑like growth factor‑1, and various peptide hormones, thereby controlling disease‑related hypersecretion.

Lanreotide may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Injection site pain or erythema
• Nausea or vomiting
• Diarrhea or abdominal cramps
• Headache
• Hyperglycemia or altered glucose tolerance
• Fatigue

Serious or Rare Side Effects

• Gallstone formation or biliary colic
• Acute pancreatitis
• Severe hyperglycemia requiring medical intervention
• Anaphylactic or severe allergic reactions
• Cardiac arrhythmias or conduction abnormalities
• Hepatic enzyme elevations

• Before initiating therapy, clinicians should consider several safety aspects.
• Monitor glucose levels: patients with diabetes may experience worsening hyperglycemia.
• Assess gallbladder status: risk of gallstone development warrants periodic imaging.
• Evaluate cardiac function: monitor for potential arrhythmias, especially in patients with pre‑existing heart disease.
• Avoid use in patients with known hypersensitivity to lanreotide or any excipients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin): may lower lanreotide plasma concentrations.
• Octreotide or other somatostatin analogs: additive hormonal suppression can increase risk of adverse effects.
• Antidiabetic agents: may need dose adjustment due to lanreotide‑induced hyperglycemia.

Moderate Interactions (Monitor Closely)

• Medications affecting gallbladder motility (e.g., ceftriaxone): monitor for gallstone formation.
• Drugs that prolong QT interval: observe cardiac rhythm for additive effects.
• Concomitant use of peptide‑based therapies: watch for overlapping side‑effect profiles.